Trials / Completed
CompletedNCT01910025
PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy
Phase 2 Study of ADI PEG 20 in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Polaris Group · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers that have arginine. In this study, the primary efficacy variable will be assessment of tumor response rate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADI-PEG 20 |
Timeline
- Start date
- 2013-12-06
- Primary completion
- 2016-08-31
- Completion
- 2017-12-15
- First posted
- 2013-07-29
- Last updated
- 2018-09-18
Locations
5 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01910025. Inclusion in this directory is not an endorsement.